Welcome to Crene Biotechnology!


Product :

Beraprost sodium

Beraprost sodium 88475-69-8
Size Price Stock Quantity
Get Quotation Now Add to Cart Bulk Inquiry
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
Product name:Beraprost sodium Purity:99% min
CAS NO:88475-69-8 Solubility:Soluble in DMSO
Molecular Formula:C24H29NaO5 Package:Packaging according to customer requirements
Molecular Weight:420.47 Storage:Store at -20℃
Quality control

Beraprost is an analog of prostacyclin in which the unstable enol-ether has been replaced by a benzofuran ether function. This modification increases the plasma half-life from 30 seconds to several hours, and permits the compound to be taken orally. Doses of 20-100 µg in humans, given 1 to 3 times per day, have been demonstrated to improve clinical end points in diseases responsive to prostacyclin. Oral beraprost therapy improved the survival and pulmonary hemodynamics of patients with primary pulmonary hypertension.1 Beraprost inhibits platelet aggregation in healthy subjects and in diabetic patients at similar doses.2,3


Beraprost sodium is a potent IP receptor agonist, inhibiting ADP-induced platelet aggregation and P-selectin expression.




Related Prodcuts: 

Latanoprost Lactol; trans-(15S)-Latanoprost; Latanoprostene bunod; 15(S)-Latanoprost; trans-Latanoprost(+)-Cloprostenol; Cloprostenol; Misoprostol; Tafluprost; Dinoprostone; Dinoprost; Trometamol; Alprostadil; Bimatoprost; (+/-)-Corey lactone diol; Limaprost Alfadex N-2; Dehydrate limaprost; Carboprost tromethamine



1. Nagaya, N.,Uematsu, M.,Okano, Y., et al. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. Journal of the American College of Cardiology 34, 1188-1192 (1999).

2. Nony, P.,Ffrench, P.,Girard, P., et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: A study in healthy male subjects. Canadian Journal of Physiology and Pharmacology 74, 887-893 (1996).

3. Kato, H.,Takashima, T.,Kishikawa, H., et al. Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus. International Journal of Clinical Pharmacology Research 16, 99-102 (1996).

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Friendly link:

Copyright Copyright (C) 2018-2021 Taizhou Crene Biotechnology Co.,Ltd.  

Address:Economic Developed Zone of Taizhou Zhejiang China